Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults

C Green; J McGinley; C Sande; S Capone; S Makvandi-Nejad; A Vitelli; L Silva-Reyes; S Bibi; C Otasowie; D Sheerin; A Thompson; C Dold; P Klenerman; E Barnes; L Dorrell; C Rollier; A Pollard; D O’Connor

doi:10.1093/cei/uxad003

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults

C Green
, J McGinley^*
, C Sande
, S Capone
, S Makvandi-Nejad
, A Vitelli
, L Silva-Reyes
, S Bibi
, C Otasowie
, D Sheerin
, A Thompson
, C Dold
, P Klenerman
, E Barnes
, L Dorrell
, C Rollier
, A Pollard
, D O’Connor

^*Corresponding author for this work

Chemical Engineering

Research output: Contribution to journal › Article › peer-review

34 Downloads (Pure)

Abstract

Cohorts of healthy younger adults (18–50yrs) and healthy older adults (60–75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert. Whole blood gene expression was measured at baseline, 3- and 7-days post vaccination. Intramuscular prime vaccination with PanAd3-RSV induced differential expression of 643 genes (DEGs, FDR < 0.05). Intranasal prime vaccination with PanAd3-RSV did not induce any differentially expressed genes (DEGs) in blood samples at 3 days post vaccination. Intranasally primed participants showed greater numbers of DEGS on boosting than intramuscularly primed participants. The most highly enriched biological processes related to DEGs after both prime and boost vaccination were type-1 interferon related pathways, lymphocytic and humoral immune responses.

Original language	English
Pages (from-to)	269–279
Number of pages	11
Journal	Clinical and Experimental Immunology
Volume	211
Issue number	3
Early online date	9 Jan 2023
DOIs	https://doi.org/10.1093/cei/uxad003
Publication status	Published - Mar 2023

Bibliographical note

Funding:
The RSV001 clinical trial was funded and sponsored by ReiThera S.r.l. (formerly Okairos S.r.l), which was acquired by GlaxoSmithKline Biologicals SA during the trial. Further funding and support was provided by the NIHR Oxford Biomedical Research and for Charles Sande and Paul Klenerman from the Wellcome Trust (WT 091663MA).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

RSV
vaccine
transcriptomics
human trials
antibodies
viral vectors

Access to Document

10.1093/cei/uxad003Licence: Creative Commons: Attribution (CC BY)

GreenC2023TranscriptomicFinal published version, 3.2 MBLicence: Creative Commons: Attribution (CC BY)

Cite this

Green, C., McGinley, J., Sande, C., Capone, S., Makvandi-Nejad, S., Vitelli, A., Silva-Reyes, L., Bibi, S., Otasowie, C., Sheerin, D., Thompson, A., Dold, C., Klenerman, P., Barnes, E., Dorrell, L., Rollier, C., Pollard, A., & O’Connor, D. (2023). Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults. Clinical and Experimental Immunology, 211(3), 269–279. https://doi.org/10.1093/cei/uxad003

@article{4df29efc4c5d478692244d5caa65d8f8,

title = "Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults",

abstract = "Cohorts of healthy younger adults (18–50yrs) and healthy older adults (60–75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert. Whole blood gene expression was measured at baseline, 3- and 7-days post vaccination. Intramuscular prime vaccination with PanAd3-RSV induced differential expression of 643 genes (DEGs, FDR < 0.05). Intranasal prime vaccination with PanAd3-RSV did not induce any differentially expressed genes (DEGs) in blood samples at 3 days post vaccination. Intranasally primed participants showed greater numbers of DEGS on boosting than intramuscularly primed participants. The most highly enriched biological processes related to DEGs after both prime and boost vaccination were type-1 interferon related pathways, lymphocytic and humoral immune responses. ",

keywords = "RSV, vaccine, transcriptomics, human trials, antibodies, viral vectors",

author = "C Green and J McGinley and C Sande and S Capone and S Makvandi-Nejad and A Vitelli and L Silva-Reyes and S Bibi and C Otasowie and D Sheerin and A Thompson and C Dold and P Klenerman and E Barnes and L Dorrell and C Rollier and A Pollard and D O{\textquoteright}Connor",

note = "Funding: The RSV001 clinical trial was funded and sponsored by ReiThera S.r.l. (formerly Okairos S.r.l), which was acquired by GlaxoSmithKline Biologicals SA during the trial. Further funding and support was provided by the NIHR Oxford Biomedical Research and for Charles Sande and Paul Klenerman from the Wellcome Trust (WT 091663MA).",

year = "2023",

month = mar,

doi = "10.1093/cei/uxad003",

language = "English",

volume = "211",

pages = "269–279",

journal = "Clinical and Experimental Immunology",

issn = "0009-9104",

publisher = "Wiley",

number = "3",

}

Green, C, McGinley, J, Sande, C, Capone, S, Makvandi-Nejad, S, Vitelli, A, Silva-Reyes, L, Bibi, S, Otasowie, C, Sheerin, D, Thompson, A, Dold, C, Klenerman, P, Barnes, E, Dorrell, L, Rollier, C, Pollard, A & O’Connor, D 2023, 'Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults', Clinical and Experimental Immunology, vol. 211, no. 3, pp. 269–279. https://doi.org/10.1093/cei/uxad003

TY - JOUR

T1 - Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults

AU - Green, C

AU - McGinley, J

AU - Sande, C

AU - Capone, S

AU - Makvandi-Nejad, S

AU - Vitelli, A

AU - Silva-Reyes, L

AU - Bibi, S

AU - Otasowie, C

AU - Sheerin, D

AU - Thompson, A

AU - Dold, C

AU - Klenerman, P

AU - Barnes, E

AU - Dorrell, L

AU - Rollier, C

AU - Pollard, A

AU - O’Connor, D

N1 - Funding: The RSV001 clinical trial was funded and sponsored by ReiThera S.r.l. (formerly Okairos S.r.l), which was acquired by GlaxoSmithKline Biologicals SA during the trial. Further funding and support was provided by the NIHR Oxford Biomedical Research and for Charles Sande and Paul Klenerman from the Wellcome Trust (WT 091663MA).

PY - 2023/3

Y1 - 2023/3

N2 - Cohorts of healthy younger adults (18–50yrs) and healthy older adults (60–75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert. Whole blood gene expression was measured at baseline, 3- and 7-days post vaccination. Intramuscular prime vaccination with PanAd3-RSV induced differential expression of 643 genes (DEGs, FDR < 0.05). Intranasal prime vaccination with PanAd3-RSV did not induce any differentially expressed genes (DEGs) in blood samples at 3 days post vaccination. Intranasally primed participants showed greater numbers of DEGS on boosting than intramuscularly primed participants. The most highly enriched biological processes related to DEGs after both prime and boost vaccination were type-1 interferon related pathways, lymphocytic and humoral immune responses.

AB - Cohorts of healthy younger adults (18–50yrs) and healthy older adults (60–75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert. Whole blood gene expression was measured at baseline, 3- and 7-days post vaccination. Intramuscular prime vaccination with PanAd3-RSV induced differential expression of 643 genes (DEGs, FDR < 0.05). Intranasal prime vaccination with PanAd3-RSV did not induce any differentially expressed genes (DEGs) in blood samples at 3 days post vaccination. Intranasally primed participants showed greater numbers of DEGS on boosting than intramuscularly primed participants. The most highly enriched biological processes related to DEGs after both prime and boost vaccination were type-1 interferon related pathways, lymphocytic and humoral immune responses.

KW - RSV

KW - vaccine

KW - transcriptomics

KW - human trials

KW - antibodies

KW - viral vectors

UR - http://dx.doi.org/10.1093/cei/uxad003

U2 - 10.1093/cei/uxad003

DO - 10.1093/cei/uxad003

M3 - Article

SN - 0009-9104

VL - 211

SP - 269

EP - 279

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

IS - 3

ER -

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this